NCT04658004 is a EARLY_PHASE1 clinical trial of NKG2D CAR T-cells in Acute Myeloid Leukemia, sponsored by Zhejiang University.

Who is sponsoring NCT04658004?

NCT04658004 is sponsored by Zhejiang University.

What drugs are being tested in NCT04658004?

Interventions in NCT04658004: NKG2D CAR T-cells.

What condition does NCT04658004 study?

NCT04658004 studies Acute Myeloid Leukemia.

Is NCT04658004 still recruiting?

NCT04658004 is currently not yet recruiting. Last updated 8 December 2020.

Last reviewed 2020-12-08 · How we verify

NCT04658004

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Not yet recruiting EARLY_PHASE1 Last updated 8 December 2020

What this trial tests

EARLY_PHASE1 trial testing NKG2D CAR T-cells in Acute Myeloid Leukemia in 36 participants. Not yet recruiting.

Timeline

15 January 2021

Primary endpoint
15 January 2024

15 January 2027

Quick facts

Lead sponsor	Zhejiang University
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	15 January 2021
Primary completion	15 January 2024
Estimated completion	15 January 2027
Sites	1 location across China

Drugs / interventions tested

NKG2D CAR T-cells — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

Zhejiang University

Who can join

Adults 3 to 70, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w
A summary of current NKG2D-based CAR clinical trials.
Curio S, Jonsson G, Marinović S. · · 2021 · cited 63× · PMID 34604863 · DOI 10.1093/immadv/ltab018
Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.
Jones AB, Rocco A, Lamb LS, Friedman GK, et al · · 2022 · cited 44× · PMID 35565467 · DOI 10.3390/cancers14092339
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C, Ruella M, Paruzzo L, Tarella C, et al · · 2024 · cited 36× · PMID 38904305 · DOI 10.1158/2643-3230.bcd-23-0202
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. · · 2022 · cited 30× · PMID 35158765 · DOI 10.3390/cancers14030497
Natural killer cells in cancer immunotherapy.
Wang D, Dou L, Sui L, Xue Y, et al · · 2024 · cited 24× · PMID 38882209 · DOI 10.1002/mco2.626
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
Schorr C, Perna F. · · 2022 · cited 21× · PMID 36605213 · DOI 10.3389/fimmu.2022.1085978
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.
Casado P, Cutillas PR. · · 2023 · cited 15× · PMID 36805445 · DOI 10.1016/j.mcpro.2023.100517

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04658004 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 8 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04658004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing